BridgeBio Pharma, Inc.
US ˙ NasdaqGS ˙ US10806X1028

SecurityBBIO / BridgeBio Pharma, Inc.
InstitutionDiversified Trust Co
Latest Disclosed Ownership43,971 shares
Latest Disclosed Value $ 3,265,286
Diversified Trust Co reports 12.17% increase in ownership of BBIO / BridgeBio Pharma, Inc.

On April 16, 2026 - Diversified Trust Co filed a 13F-HR form disclosing ownership of 43,971 shares of BridgeBio Pharma, Inc. (US:BBIO) valued at $3,265,286 USD as of March 31, 2026. The entity filed a previous 13F-HR on January 9, 2026 disclosing 39,201 shares of BridgeBio Pharma, Inc.. This represents a change in shares of 12.17% during the quarter. The current value of the position is $2,879,221 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-04-16 2026-03-31 13F BRIDGEBIO PHARMA COM 10806X102 43,971 4,770 12.17 3,265 8.91 0.0606
2026-01-09 2025-12-31 13F BRIDGEBIO PHARMA COM 10806X102 39,201 -1,385 -3.41 2,998 42.22 0.0552
2025-10-20 2025-09-30 13F BRIDGEBIO PHARMA COM 10806X102 40,586 1,981 5.13 2,108 26.53 0.0421
2025-07-11 2025-06-30 13F BRIDGEBIO PHARMA COM 10806X102 38,605 3,739 10.72 1,667 38.26 0.0370
2025-04-24 2025-03-31 13F BRIDGEBIO PHARMA COM 10806X102 34,866 7,039 25.30 1,205 57.93 0.0298
2025-01-07 2024-12-31 13F BRIDGEBIO PHARMA COM 10806X102 27,827 -8,945 -24.33 764 -18.48 0.0186
2024-10-07 2024-09-30 13F BRIDGEBIO PHARMA COM 10806X102 36,772 1,059 2.97 936 3.54 0.0236
2024-07-16 2024-06-30 13F BRIDGEBIO PHARMA COM 10806X102 35,713 8,011 28.92 905 5.61 0.0256
2024-04-18 2024-03-31 13F BRIDGEBIO PHARMA COM 10806X102 27,702 10,066 57.08 857 20.39 0.0258
2024-01-08 2023-12-31 13F BRIDGEBIO PHARMA COM 10806X102 17,636 525 3.07 712 57.65 0.0239
2023-11-17 2023-09-30 13F BRIDGEBIO PHARMA COM 10806X102 17,111 411 2.46 451 57.14 0.0171
2023-07-18 2023-06-30 13F BRIDGEBIO PHARMA COM 10806X102 16,700 16,700 287 0.0105
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.